Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

26.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,015
Open 26.71
Bid (Size) 28.10 (8)
Ask (Size) 28.46 (1)
Prev. Close 26.71
Today's Range 26.71 - 26.71
52wk Range 20.84 - 49.50
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
-2.55%
-2.55%
1 Month
-1.29%
-1.29%
3 Month
+14.15%
+14.15%
6 Month
+9.47%
+9.47%
1 Year
+0.23%
+0.23%

More News

Read More
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
From Beam Therapeutics
Via GlobeNewswire
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Beam Therapeutics's Earnings: A Preview
Via Benzinga
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Via Benzinga
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
Via Benzinga
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
Via Benzinga
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
From Beam Therapeutics
Via GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Via InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
From Beam Therapeutics
Via GlobeNewswire
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Via Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
Via Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.